Bio-Thera(SH:688177)2024-07-29 07:54Financial Performance - The net profit attributable to the parent company is expected to be between -220 million and -280 million yuan for the first half of 2024, continuing to incur losses compared to the same period last year [7]. - The net profit attributable to the parent company, excluding non-recurring gains and losses, is projected to be between -250 million and -310 million yuan [15]. - The company's operating revenue is expected to increase by 60 million to 90 million yuan compared to the same period last year, driven by market expansion and increased sales of the drug Geleli [12]. - The performance for the first half of 2024 shows no significant changes compared to the same period last year [12]. Sales and Market Expansion - The overseas sales revenue has increased year-on-year following the approval and launch of the drug Tocilizumab injection in the US in May 2024 [12]. Earnings Forecast and Risks - The company confirms that there are no significant uncertainties affecting the accuracy of this earnings forecast [4]. - The earnings forecast has not been audited by a registered accountant [10]. - The company emphasizes the importance of investors being aware of investment risks related to the preliminary earnings data [10]. - The board of directors guarantees the truthfulness, accuracy, and completeness of the announcement content [6]. - The company will provide more accurate financial data in the official 2024 semi-annual report [10].